Bluejay Diagnostics, Inc.

General Information
Business:

We are a late-stage pre-revenue company focused on improving patient outcomes through a more cost efficient, rapid, near patient product for triage, diagnosis and monitoring of disease progression. We believe there is a market need for an on-site and rapid diagnostic system that can be employed for testing and monitoring. Our diagnostic system, which we refer to as “Symphony,” is an exclusively licensed, patented, low-cost, system that consists of a small footprint instrument and single-use indication specific test cartridges, that we believe, if cleared, authorized, or approved by the U.S. Food and Drug Administration (“FDA”), can provide a solution to this market need rapidly and with laboratory quality results in approximately 24 minutes, in the clinic, Intensive Care Unit (“ICU”), Emergency Room (“ER”) and in other hospital and clinical setting settings where a rapid and reliable results are required. Currently, testing is generally performed in a laboratory, and the transportation and logistics of transporting the samples to the lab and obtaining the result takes between 8-48 hours.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 5
Founded: 2015
Contact Information
Address 360 Massachusetts Avenue, Suite 203, Acton, MA 01720, US
Phone Number (844) 327-7078
Web Address
View Prospectus: Bluejay Diagnostics, Inc.
Financial Information
Market Cap $123.5mil
Revenues $0 mil (last 12 months)
Net Income $-1.1 mil (last 12 months)
IPO Profile
Symbol BJDX
Exchange NASDAQ
Shares (millions): 2.2
Price range $10.00 - $10.00
Est. $ Volume $21.6 mil
Manager / Joint Managers Dawson James Securities/ I-Bankers Direct, LLC
CO-Managers -
Expected To Trade: 11/10/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change